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Acute kidney injury in critically ill patients is often a complication of an
underlying condition such as organ failure, sepsis, or drug therapy.  In these
patients, stress-induced hypercatabolism results in loss of body cell mass.
Unless nutrition support is provided, malnutrition and negative nitrogen
balance may ensue.  Because of metabolic, fluid, and electrolyte abnormalities,
optimization of nutrition to patients with acute kidney injury presents a
challenge to the clinician.  In patients treated with conventional intermittent
hemodialysis, achieving adequate amino acid intake can be limited by
azotemia and fluid restriction.  With the use of continuous renal replacement
therapy (CRRT), however, better control of azotemia and liberalization of
fluid intake allow amino acid intake to be maximized to support the patient’s
metabolic needs.  High amino acid doses up to 2.5 g/kg/day in patients treated
with CRRT improved nitrogen balance.  However, to our knowledge, no
studies have correlated increased amino acid intake with improved outcomes
in critically ill patients with acute kidney injury.  Data from large, prospective,
randomized, controlled trials are needed to optimize the dosing of amino
acids in critically ill patients with acute kidney injury who are treated with
CRRT and to study the safety of high doses and their effects on patient
morbidity and survival.
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Conclusion
The classic nomenclature “acute renal failure”
is being replaced by the more current
terminology “acute kidney injury,” driven by the
Acute Dialysis Quality Initiative (ADQI) group
proposal for a consensus definition of acute renal
failure.  The ADQI consensus definition of acute
kidney injury is denoted by the acronym RIFLE,
which refers to three stages by increasing severity
(risk, injury, failure) based on combined criteria
of serum creatinine concentration or glomerular
filtration rate and urine output, as well as two
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outcomes (loss and end-stage kidney disease) in
relation to kidney function.1 In a retrospective
study that used the RIFLE classification for the
definition of acute kidney injury in the analysis
of a database of 41,972 patients from 22 intensive
care units (ICUs), patients with risk, injury, and
failure had corresponding mortality rates of
20.9%, 45.6%, and 56.8%, respectively.2 In a
multinational, multicenter, prospective, epidemi-
ologic survey of acute kidney injury in ICUs that
included a total of 29,269 critically ill patients,
1738 patients (5.9%) developed acute kidney
injury sometime during their ICU stay, including
1260 patients (4.3% of critically ill patients or
72.5% of patients with acute kidney injury) who
were managed with renal replacement therapy
(defined as peritoneal dialysis or any technique
of renal support requiring an extracorporeal
circuit and an artificial membrane).3 Hospital
and ICU mortality rates in patients with acute
kidney injury who were treated with renal replace-
ment therapy were 55% and 64%, respectively.4
Malnutrition is common in patients with acute
kidney injury and is caused by anorexia, impaired
protein metabolism and transport, oxidative
stress, metabolic acidosis, nutrient losses through
the hemodiafilter, and patient comorbidities.
Because acute kidney injury in critically ill
patients commonly occurs in the setting of other
diseases, nutritional and metabolic changes are
the result of underlying conditions such as
surgery, trauma, burns, organ failure, and sepsis,
rather than acute kidney injury alone.  Proper
nutrition is aimed at minimizing the effects of
hypermetabolism and hypercatabolism and
improving patient recovery.5, 6
Critically ill patients with acute kidney injury
frequently have azotemia and fluid overload, and
may not tolerate high fluid removal rates during
intermittent hemodialysis over a 3–4-hour period.
Patients who are managed with intermittent
hemodialysis 3 times/week may need fluid
restriction, and the ability to meet their higher
amino acid requirements to compensate for
hypercatabolism is often hindered by accumu-
lation of nitrogenous waste.  Although intermit-
tent hemodialysis 3 times/week is common
practice, critically ill patients with acute kidney
injury may require more frequent intermittent
hemodialysis to achieve metabolic and azotemic
control.  More frequent intermittent hemodialysis
may allow more fluid intake depending on the
patient’s fluid status and tolerance.  However,
with continuous renal replacement therapy
(CRRT), enhanced nitrogenous waste clearance
and liberalization of fluid intake allow increasing
amino acid intake to meet the patient’s metabolic
requirements.  The preferred choice of dialysis in
hemodynamically unstable patients is CRRT
because it allows for slow continuous fluid
removal and superior hemodynamic and
metabolic control compared with intermittent
hemodialysis.7 There is wide variation with the
modalities and types of renal replacement
therapies used in hospitals, and available data on
amino acid dosing in patients treated with CRRT
are limited by study designs.
Metabolic Effects of Acute Kidney Injury and
Energy Requirements
Physiologic and metabolic functions of the
kidneys include acid-base balance and regulation
of fluids and electrolytes; excretion of metabolic
end-products (e.g., urea), toxins, and drugs;
production and secretion of enzymes (e.g., renin,
angiotensin) and hormones (e.g., erythropoietin,
vitamin D3); and metabolic conversions (e.g.,
gluconeogenesis, lipid metabolism, ammonia-
genesis).  Significant changes to normal kidney
functions occur with acute kidney injury that
adversely impact the metabolic and nutritional
status of the patient.6
The hypermetabolic and hypercatabolic
responses to stress or injury affect the nutritional
requirements of critically ill patients with acute
kidney injury. The metabolic response causes
increased production of stress mediators
including cytokines (interleukin-1, interleukin-6,
tumor necrosis factor-a), counterregulatory
hormones (catecholamines, cortisol, glucagon),
and immune mediators (thromboxane A2,
prostaglandin F2a, prostaglandin E2).  Stress
mediators cause proteolysis, glycogenolysis,
gluconeogenesis, and lipolysis.  As a result,
critically ill patients have skeletal muscle
breakdown, impaired amino acid transport into
skeletal muscles, suppressed insulin-mediated
601
From the Department of Clinical, Social, and
Administrative Sciences, University of Michigan College of
Pharmacy, and the Department of Pharmacy Services,
University of Michigan Hospitals and Health Centers, Ann
Arbor, Michigan (Drs. Btaiche, Alaniz, and Mueller); and
the Division of Pharmacy Practice, Arnold and Marie
Schwartz College of Pharmacy and Health Sciences, Long
Island University, and Mount Sinai Hospital, New York, New
York (Dr. Mohammad).
Address reprint requests to Imad F. Btaiche, Pharm.D.,
BCNSP,  Department of Pharmacy Services, UH B2 D301
Box 0008, University of Michigan Hospitals and Health
Centers, 1500 East Medical Center Drive, Ann Arbor, MI
48109-0008; e-mail:  imadb@umich.edu.
PHARMACOTHERAPY  Volume 28, Number 5, 2008
protein synthesis, depletion of body energy
reserves and constitutive proteins, increased urea
production, and peripheral insulin resistance.
Protein catabolism is further exacerbated by
metabolic acidosis that is typically seen in
patients with acute kidney injury.  The conse-
quences of these metabolic derangements are
manifested by loss of body energy reserves
(glycogen, protein, and fat stores), negative
nitrogen balance, hyperglycemia, and hyper-
triglyceridemia.8, 9
Acute kidney injury affects protein degradation
and amino acid conversions due to impaired
kidney metabolic functions.  Serum amino acid
concentrations such as phenylalanine, methionine,
taurine, and cysteine are typically elevated,
whereas serum valine and leucine concentrations
are decreased in patients with acute kidney
injury.  Also, nonessential dispensable amino
acids (e.g., tyrosine, arginine) become condi-
tionally essential or indispensable, and phenyl-
alanine conversion to tyrosine becomes inade-
quate in these patients.10, 11 Further, critical
illness and sepsis cause changes in the serum
amino acid profile, with increased glutamine
degradation and decreased serum phenylalanine
concentrations.12, 13
Glutamine is the most abundant amino acid in
skeletal muscles, is an essential fuel for enterocytes,
and becomes conditionally essential or indispensable
under metabolic stress.14 Glutamine is also cleared
in the effluent during CRRT.  A study of critically
ill adult patients with multiorgan dysfunction
syndrome who were treated with CRRT and who
received supplemental intravenous glutamine 0.5
g/kg over 20 hours for 2 days reported glutamine
losses of 0.5–6.8 g/day through the hemo-
diafilter.15 Glutamine clearance correlated with
plasma glutamine concentrations and the effluent
flow rate.  The investigators suggested that
glutamine be supplemented at 20 g/day in
critically ill adult patients treated with CRRT.
Glutamine is not a standard component of
parenteral amino acid solutions, and the benefits
of glutamine supplementation in critically ill
patients remain debatable.16
Because energy requirements for critically ill
patients vary with the level of metabolic stress,
patient energy expenditure is best measured by
using indirect calorimetry measurements.
Although it is estimated that adult patients with
acute kidney injury require total calories of
25–35 kcal/kg/day, indirect calorimetry provides
a more accurate measurement of patient’s energy
expenditure while avoiding overfeeding.6 A
considerable amount of dextrose at about
35–45% of dialysate dextrose is absorbed during
hemodiafiltration when dextrose-containing
dialysate is used.5 Dextrose contribution from
dialysate should be included in the calculation of
dextrose calories when designing a nutrition
support regimen.  Dextrose overfeeding results in
hepatic steatosis and hyperglycemia.17 Hyper-
glycemia enhances protein catabolism and increases
patient morbidity and mortality.18 Because dextrose
uptake to the patient with dextrose-containing
dialysate is much greater than dextrose loss,
which is minor and of no clinical significance,
use of dextrose-free dialysate and replacement
fluid with CRRT is recommended.19
Assessment of Body Protein Status and Extent
of Protein Catabolism
Methods to assess a patient’s protein status
include anthropometric measurements of the
midarm circumference, biochemical measure-
ments of serum visceral proteins, nitrogen balance
studies, urea nitrogen appearance (UNA), and
protein catabolic rate (PCR).  Each of these methods
has limited specificity or sensitivity in critical
illness.  Midarm circumference measurement to
assess muscle mass is limited in the critically ill
patient by fluid overload and patient positioning.
Although serum visceral proteins (albumin,
prealbumin, retinol-binding protein, transferrin)
are clinically useful measurements of the patient’s
protein-calorie status, they are negative acute
phase proteins and their serum concentrations
are influenced by nonnutritional factors such as
stress level, inflammation, and hydration status.20
Nitrogen Balance
Nitrogen balance describes the difference
between body nitrogen gains and losses.
Measuring nitrogen balance is based on the
premise that nitrogen equilibrium is attained
when protein supply is adequate to replace
nitrogen loss through the urine, stools, wounds,
desquamation of epithelial cells, and sweat.  Most
body nitrogen is contained in proteins, with
nitrogen accounting for about 16% (assumption
that protein is composed of 16% nitrogen [1/6.25
= 0.16]) of protein structure.21 Nitrogen is
released during protein catabolism and is mostly
excreted in the urine in the form of urea.  A
positive nitrogen balance is a reflection that
nitrogen intake exceeds nitrogen loss.  A desired
positive nitrogen balance is in the range of 4–6
g/day.  However, protein catabolism and negative
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nitrogen balance are unavoidable in the critically
ill patient, and attaining a positive nitrogen
balance is often difficult to achieve until the
patient’s metabolic stress resolves.  In the stressed
critically ill patient, nitrogen balance data may
actually represent the degree of catabolism rather
than the adequacy of protein intake.  The time to
achieve a zero nitrogen balance or nitrogen
equilibrium varies among patients and from day
to day depending on the type and degree of injury,
comorbidities, metabolic stress, nutritional status,
and nutritional intake.  In the short term, nitrogen
equilibrium in the nonanabolic, noncatabolic
metabolically stable adult may be achieved in 5–7
days with adequate energy and protein intake.
However, improved nitrogen balance has not
necessarily been shown to be associated with
enhanced muscle protein synthesis such as in
critically ill patients receiving parenteral nutrition.22
In the nonstressed patient, urinary urea nitrogen
(UUN) accounts for 80–90% of total urinary
nitrogen.  This estimate is not valid in critically
ill patients and those with acute kidney injury,
liver failure, or sepsis.  Under these conditions,
the percentage of nonurea urinary nitrogen
components varies widely with the formation of
nonurea nitrogen substances such as ammonia
and uric acid.23 Although measuring total
urinary nitrogen is more accurate than UUN,
laboratory measurement of total urinary nitrogen
is extremely laborious.  In addition, variations in
nitrogen losses and the inability to accurately
account for all nonurine nitrogen losses lead to
problems in interpreting nitrogen balance
studies.  Because of limited laboratory resources,
clinicians commonly rely on the measurement of
UUN and use adjustment formulas to compensate
for insensible nitrogen losses and nonurea
nitrogen components.  Equations used to measure
nitrogen balance are as follows:  nitrogen balance
(g/day) = nitrogen intake (g/day) – nitrogen
losses (g/day); nitrogen losses = UUN + nonurea
urinary nitrogen (2 g) + fecal nitrogen (2 g).
Urea Nitrogen Appearance
A less laborious method used to measure the
net rate of protein catabolism is UNA, which
refers to urea in body fluids such as urine or
output from fistulas and in dialysate.  In patients
treated with intermittent hemodialysis, UNA is
calculated as follows24: UNA (g/day) = UUN
(g/day) + dialysate urea nitrogen (g/day) +
change in body urea nitrogen (g/day); change in
body urea nitrogen (g/day) = [(BUNf – BUNi) x
BWi x 0.6 L/kg] + [(BWf – BWi) x BUNf x 1
L/kg], where BUN is blood urea nitrogen
expressed in g/L and BW is body weight in kg.
The i and f represent the initial (immediately
after dialysis) and final (immediately before the
second dialysis session) values for the period of
measurement, respectively.  The factor of 0.6 is
an estimate of the fraction of adult body weight
as water, and 1 is the fractional distribution of
urea in the gained or lost weight.25
For patients treated with CRRT, urea is
collected and measured in the ultrafiltrate and
dialysate and added to the UUN and changes in
body urea nitrogen.  Nitrogen balance can then
be calculated as follows:  nitrogen balance =
nitrogen intake – (UNA + other nitrogen losses).
Other nitrogen losses in the range of 4–6 g/day
include nitrogen loss during dialysis, in stools,
through drainage, and other minor nitrogen
losses through skin and sweat.
Protein Catabolic Rate
The PCR, also called protein equivalent of
nitrogen appearance, is a measure of net protein
degradation and is used to estimate protein
intake.  Under steady-state conditions, protein
intake is equal or slightly greater than PCR.
Because protein requirements are based on
adjusted edema-free body cell mass, PCR is
normalized to be expressed in grams of protein
degraded daily divided by the dry body weight
and is labeled as normalized PCR (nPCR).
Limitations to nPCR include its wide variation in
metabolically unstable patients, its rapid fluctu-
ations with changes in protein intake, and its
underestimation of protein intake when protein
intake is high and overestimation of protein
intake when protein intake is less than 1
g/kg/day.20 The PCR is calculated as follows26:
PCR (g/day) = UNA x 6.25.
The PCR closely correlates with protein intake
only in the steady state of nitrogen equilibrium.
Although PCR has been used in clinical studies
of patients with acute kidney injury managed
with CRRT, wide variations in PCR values have
been reported, mainly in clinically unstable
patients.27–29 Repeat measurements of PCR are
thus needed, as daily PCR, determined by single-
day nitrogen balance studies, overestimates protein
requirements in some patients and underestimates
it in others.30
In a group of 10 adult patients with acute
kidney injury managed with conventional 4-hour
hemodialysis or 8-hour sustained low-efficiency
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dialysis and who received fixed amino acid doses
at 1.5 g/kg/day, mean PCR was 1.47 g/kg/day
(range 0.97–1.8 g/kg/day).31 Critically ill adult
patients with acute kidney injury managed with
CRRT who received an average amino acid intake
of 1.4 g/kg/day had a mean PCR of 1.7 g/kg/day.30
Another study of critically ill adult patients with
acute kidney injury managed with CRRT
reported a mean ± SD nPCR of 1.82 ± 0.95
g/kg/day.27 This is in agreement with results from
patients with acute kidney injury treated with
different CRRT modalities who had a mean ± SD
nPCR of 1.75 ± 0.82 (range 0.61–4.23
g/kg/day).28 Higher PCR is expected in highly
catabolic patients with severe burn injuries.
Critically ill adult patients with acute kidney
injury treated with CRRT who received amino
acids at 1.8 + 0.4 g/kg/day had a higher PCR of
2.2 g/kg/day (range 1.2–4 g/kg/day).29
Amino Acid Requirements
Amino acids are nitrogenous compounds used
as energy source and building blocks for proteins.
Restriction of amino acid intake in patients with
acute kidney injury is aimed at avoiding frequent
dialysis caused by azotemia due to accumulation
of nitrogenous waste.  The National Kidney
Foundation Kidney Disease Outcomes Quality
Initiative recommendation for amino acid intake
in adult patients with chronic renal failure kidney
disease before dialysis is 0.6–0.75 g/kg/day; in
clinically stable patients undergoing maintenance
hemodialysis, 1.2 g/kg/day; in patients receiving
long-term peritoneal dialysis, 1.2–1.3 g/kg/day;
and in acutely ill patients receiving maintenance
hemodialysis, at least 1.2–1.3 g/kg/day.20 For
critically ill patients without renal or liver
disease, higher amino acid doses of 1.5–2
g/kg/day are often used clinically.
In patients with acute kidney injury who are
highly catabolic and severely malnourished, the
American Society for Parenteral and Enteral
Nutrition practice guidelines recommend amino
acid intake at 1.5–1.8 g/kg/day.32 In patients
treated with CRRT, amino acid doses ranged from
1.2–2.5 g/kg/day.  Because CRRT provides a
superior control of azotemia compared with
intermittent hemodialysis, higher amino acid
intake is possible without worsening azotemia.33
Early developed specialized parenteral and
enteral amino acid formulations that primarily
provided essential amino acids were aimed at
forcing the recycling of urea nitrogen for the
synthesis of nonessential amino acids and to
avoid worsening of azotemia.  The rationale and
efficacy of these products were questioned
especially because of the inefficiency of urea
recycling under stress34, 35 and because some
nonessential dispensable amino acids become
conditionally essential or indispensable in
patients with acute kidney injury.36, 37 Therefore,
the use of predominantly essential amino acid
formulations has been abandoned, and standard
products with a balanced mix of essential and
nonessential amino acids are now clinically used.
However, due to significant physiologic pertur-
bations affecting amino acid balance in critically
ill patients with acute kidney injury, the amino
acid composition of standard parenteral amino
acid formulations may not be optimal to normalize
the plasma amino acid profile in these patients.
Role of Renal Replacement Therapy
Renal replacement therapy has supplanted
intermittent hemodialysis as the preferred
dialytic therapy in many ICUs.38 With CRRT, the
most critically ill patients can receive adequate
renal supportive therapy, and it may confer a
survival advantage over intermittent hemodialysis.39
Because this therapy comes in many forms, an
international consensus conference gave CRRT
modalities standard definitions.40 The two most
commonly used forms of CRRT are continuous
venovenous hemofiltration (CVVH) and continuous
venovenous hemodialysis (CVVHD).  The CVVH
form provides convective solute clearance and
consequently removes larger solutes than with
the diffusive clearance of CVVHD.  A hybrid of
CVVH and CVVHD is continuous venovenous
hemodiafiltration (CVVHDF) in which dialysate
is used with additional fluid (ultrafiltrate)
removed for additional convective clearance.
Solute removal with any modality is dependent
on the amount of effluent (dialysate and/or
ultrafiltrate) coming out of the filter and the
ability of the solute to cross the hemodiafilter.
The ability of a solute to cross the hemodiafilter
membrane is calculated by measuring the solute
concentration in the effluent and dividing by the
simultaneous concentration of the blood entering
into the hemodiafilter.  The ratio of the effluent
to blood concentration is called the sieving coeffi-
cient in CVVH or the equilibration coefficient in
CVVHD and CVVHDF.  If the coefficient is near
1, then the solute is readily cleared by CRRT,
whereas a coefficient near zero reflects poor
clearance.41 Solute molecular weight for most
nutrients is typically not an important determi-
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nant in solute removal by CRRT.  Contemporary
hemodiafilters can effectively remove substances
with molecular weights up to 5000 daltons.  A
more important determinant of a solute’s sieving
or equilibration coefficient is the degree of
protein binding.  Unbound solutes can usually
cross the hemodiafilter membrane, but if they are
bound to large proteins like albumin (molecular
weight > 66,000 daltons), they will be unable to
pass through the hemodiafilter.  Multiplication of
the solute’s sieving coefficient (with CVVH) or
equilibration coefficient (with CVVHD or
CVVHDF) by the effluent rate yields the solute’s
clearance rate.42 In addition to urea clearance,
calculation of CRRT removal of drugs and
nutritional components including amino acids is
essential.6, 43
Factors Impacting Protein and Amino Acid
Clearance Across Hemodiafilters
Small amounts of small proteins, peptides, and
cytokines are eliminated in the effluent of renal
replacement therapies.44 High-flux hemodia-
filters during a 4-hour conventional hemodialysis
session cause insignificant dialysate albumin loss
(< 0.5 g).  However, superflux or protein-leaking
membranes, although rarely used clinically, allow
the passage of low-molecular-weight and protein-
bound solutes with albumin losses of 2–6 g
during a 4-hour hemodialysis session.45 Minimal
amounts of proteins of 1.6 g/day were lost in the
effluent during CRRT when a polysulfone
hemodiafilter membrane (mean ± SD effluent rate
1637 ± 694 ml/hr) was used.  Significantly higher
protein losses occurred with CVVH than with
CVVHDF (2.2 vs 1 g/day, p=0.049).46
Amino acids have small molecular weights
(average 140 daltons, range 75–215 daltons),
with a sieving coefficient of 1, which makes their
effluent losses with CRRT far greater than that for
proteins.  Amino acid effluent clearance depends
on the duration of dialysis, dialysate flow rate,
effluent rate, and types of hemodiafilter mem-
branes.44 During an intermittent hemodialysis
session, mean ± SD amino acid dialysate losses
were 12.6 ± 3.6 g during parenteral amino acid
and glucose infusion.47 Mean dialysate amino
acid losses were 5.2 ± 0.6 g during intermittent
hemodialysis, and 7.3 ± 1.8 g during high-flux
hemodialysis.48 During a 3-hour hemodialysis
session using a polyacrylonitrile membrane,
mean amino acid dialysate losses were about 6 g,
twice the losses observed with the polysulfone
membrane.49 During a 4-hour hemodialysis
session using polysulfone and polymethyl-
methacrylate membranes, mean± SD amino acid
dialysate losses were 8 ± 2.8 g and 6.1 ± 1.5 g,
respectively.50 When intradialytic parenteral
amino acids were administered, amino acid
dialysate losses were 12 ± 2 g during a 4-hour
hemodialysis session.51 With slow diurnal
hemodialysis (a hybrid of CRRT and intermittent
hemodialysis with typical treatment duration of
6–12 hrs), mean ± SEM amino acid loss during a
10-hour dialysis session was 6.2 ± 0.6 g/day,
equivalent to 16% of daily parenteral amino acid
intake.52
Amino Acid Requirements with Continuous
Renal Replacement Therapy
In a case report of a patient treated with
CVVH, amino acid effluent losses correlated with
the effluent rate.  Doubling the ultrafiltration rate
from 0.5 to 1 L/hour caused a greater than 3
times increase in mean amino acid ultrafiltrate
losses, from 2.4 to 7.9 g/day, respectively.53
Several clinical studies evaluated the effects of
different CRRT modalities on amino acid
clearance and requirements in critically ill
patients with acute kidney injury (Table 1).54–63
A prospective, nonrandomized study evaluated
the effects of CVVH on effluent amino acid
clearance in eight critically ill adult patients with
acute kidney injury.54 Patients received parenteral
nutrition that provided 1 L of amino acids with
1850 kcal of nonprotein calories.  Study results
showed that all amino acids were cleared in the
ultrafiltrate.  A positive correlation was shown
between serum amino acid concentrations and
ultrafiltrate amino acid losses.  Patients with
cardiogenic shock had a higher total ultrafiltrate
amino acid loss of 7.4 g/day (11% of daily amino
acid intake) compared with patients with sepsis,
who had amino acid losses of 3.8 g/day (5.6% of
daily amino acid intake).  Patients with cardio-
genic shock had higher serum amino acid concen-
trations than patients with sepsis, which may
have resulted in higher amino acid clearance.
One prospective, randomized, crossover study
evaluated the effects of CVVH and CVVHD on
effluent amino acid clearance and nitrogen
balance in six critically ill pediatric patients with
acute kidney injury.55 Patients received parenteral
nutrition that provided amino acids at 1.5 g/kg/day
with a caloric intake at 120–130% of measured
resting energy expenditure.  Study results showed
a 30–40% higher amino acid clearance (except
for glutamine) with CVVH compared with
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Table 1.  Clinical Studies of Amino Acid Requirements in Critically Ill Patients with Acute Kidney Injury Treated with
Continuous Renal Replacement Therapy
Patient CRRT Modality and
Study Design Population Effluent Rate Amino Acid and Caloric Intake Primary End Points
Prospective, Adults (n=8) CVVH, Parenteral nutrition: Amino acid losses
nonrandomized54 high-flux; amino acids 1 L/day, across hemodiafilter
1 L/hr nonprotein calories
1850 kcal/day
Prospective, Children (n=6) CVVH, Parenteral nutrition: Amino acid losses
randomized, CVVHD; amino acids 1.5 g/kg/day, across hemodiafilter,
crossover55 2 L/hr calories 1.2–1.3 x resting nitrogen balance
energy expenditure
Prospective, Adults (n=6) CAVHD; Parenteral nutrition: Amino acid losses
nonrandomized56 1 or 2 L/hr amino acids 56–112 g/day, across hemodiafilter
nonprotein calories
2000–2400 kcal/day
Prospective, Adults: CAVHD, Parenteral nutrition: Amino acid losses
nonrandomized, treatment group CVVHD; Treatment group: amino across hemodiafilter
unblinded57 (n=17), 0.9 or 1.8 acids 2.19 ± 0.48 g/kg/day,
control group L/hr nonprotein calories
with normal 3077 ± 1018 kcal/day
renal function Control group: amino acids
(n=15) 2.24 ± 0.36 g/kg/day,
nonprotein calories
3015 ± 753 kcal/day
Prospective, Adults with MODS CAVHD; Parenteral nutrition: Nitrogen balance
cohort, and APACHE II 1 or 2 L/hr amino acids 1.25–1.87
interventional58 score of 28.2 (n=9) g/kg/day, nonprotein
calories 1850 kcal/day
Prospective, Adults with CVVH; No nutrition (n=6) Nitrogen balance,
nonrandomized, APACHE II score 1 L/hr Enteral and/or parenteral protein catabolism,
noninterventional59 of 25 ± 9 (n=40) nutrition (n=34): amino acids < 1 vs
amino acids 1 ± 0.4 (range ≥ 1 g/kg/day
0.3–1.9) g/kg/day,
nonprotein calories 28 ± 9
(range 13–53) kcal/kg/day
Prospective, Adults with CVVHD; Parenteral nutrition: Effects of amino acid
interventional60 APACHE II score 2 L/hr amino acids 1 g/kg/day intake on serum amino
of 20.5 ± 7 (n=11); increased by 0.25 g/kg/day acid concentrations,
3 had multiple to 2.5 g/kg/day, nonprotein amino acid balance,
trauma, 2 had calories 2585 kcal/day amino acid losses
extensive burns across hemodiafilter
Prospective, Adults with CVVHD; Parenteral and/or enteral Nitrogen balance,
interventional61 APACHE II score 2 L/hr nutrition: survival
of 26 ± 8: Treatment group:
treatment group amino acids 1.5 g/kg/day x 2
(n=40), days, then 2 g/kg/day x 2 days,
control group then 2.5 g/kg/day x 2 days
(n=10) Control group:
amino acids 2 g/kg/day,
calories 2101 ± 410 kcal/day
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CVVHD.  No significant difference was noted
between CVVH and CVVHD on calculated amino
acid loss (mean ± SEM 12.5 ± 1.3 and 11.6 ± 1.8
g/day/1.73 m2, respectively).  Mean nitrogen
balance was negative with both CVVH and
CVVHD (-3.68 ± 3.1 and -0.44 ± 1.7 g /day/1.73
m2, respectively).  Amino acid loss averaged 12%
and 11% of the daily amino acid infusion with
CVVH and CVVHD, respectively.  The investigators
speculated that higher amino acid intake is
needed in these patients to achieve a positive
nitrogen balance.  Because pediatric patients have
higher amino acid requirements than that of
adult patients, data derived from this study in
children may not necessarily apply to adults.
A correlation between dialysate flow rate and
effluent amino acid loss was reported with
continuous arteriovenous hemodialysis (CAVHD)
and CVVHD.56, 57 A prospective, nonrandomized
study evaluated effluent amino acid losses in six
critically ill adult patients treated with CAVHD.56
Daily parenteral nutrition provided amino acids
at 56 g in 1 patient, 87 g in 2 patients, and 112 g
in 3 patients.  Nonprotein calories ranged from
2000–2400 kcal/day.  Study results showed a
mean 36% higher effluent amino acid loss as a
percentage of amino acid intake at a dialysate
flow rate of 2 L/hour compared with 1 L/hour
(12.1 ± 2.2% vs 8.9 ± 1.2%).  This translates to
daily amino acids losses of 6.7, 10, and 13.6 g
with the dialysate flow rate of 2 L/hr and 4.9, 7.7,
and 10 g for the dialysate flow rate of 1 L/hr of
the respective daily amino acid intake of 56, 87,
and 112 g.
Similarly, a prospective, nonrandomized,
nonblinded study of 17 adult trauma patients
with acute kidney injury evaluated the effects of
CAVHD or CVVHD on amino acid clearance
compared with a control group of similar patients
with normal renal function.57 Amino acid intake
was similar at mean ± SD 2.19 ± 0.48 and 2.24 ±
0.36 g/kg/day in the study and control groups,
respectively.  Caloric intake was also similar, with
nonprotein calories at 3077 ± 1018 and 3015 ±
753 kcal/day in the study and control groups,
respectively.  Study results showed no significant
difference in amino acid losses between CAVHD
and CVVHD.  Amino acid losses were signifi-
cantly higher at a dialysate flow rate of 1.8
L/hour compared with a dialysate rate of 0.9
L/hour (7.9 ± 2.6 and 5.7 ± 1.7 g/12 hrs,
respectively, p<0.0001), equivalent to daily amino
acids losses at about 16 and 11 g, respectively.
Predictors of effluent amino acid losses were
serum amino acid concentrations during the
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Table 1.  (continued)
Results
All amino acids cleared in ultrafiltrate
Amino acid losses correlate with serum amino acid
concentrations and clinical condition
Cardiogenic shock: amino acid loss 7.4 g/day (11% of 
amino acid intake)
Sepsis: amino acid loss 3.8 g/day (5.6% of amino acid intake)
Serum amino acid concentrations within normal ranges
except for high serum phenylalanine and low serum
glutamine concentrations in both groups of cardiogenic
shock and sepsis
For all amino acids (except glutamine): 30–40% greater
losses with CVVH vs CVVHD
No significant difference in amino acid losses as percentage
of intake with CVVH (12%) vs CVVHD (11%)
Negative nitrogen balance, but no significantly different
effect on nitrogen balance between CVVH and CVVHD
(-3.68 ± 3.1 vs -0.44 ± 1.7 g/day/1.73 m2)
Amino acid losses as percentage of intake were higher at
effluent rate of 2 L/hr (12.1 ± 2.2%) vs 1 L/hr (8.9 ± 1.2%)
Higher amino acid losses at effluent rate of 1.8 L/hr
(7.9 ± 2.6 g/12 hrs) vs 0.9 L/hr (5.7 ± 1.7 g/12 hrs,
p<0.0001)
Amino acid losses as percentage of intake higher at effluent
rate of 1.8 L/hr (6.4 ± 2.5%) vs 0.9 L/hr (4.8 ± 1.5%,
p<0.0001)
No significant difference in amino acid losses between
CAVHD and CVVHD
Amino acid losses correlated with serum amino acid
concentrations but not with amino acid intake
Effluent glutamine loss (2 g/day) with CVVHD but not
resulting in glutamine deficiency
Effluent nitrogen losses (24.1 g/day) exceeded intake
(20.5 g/day)
Negative nitrogen balance (-3.6 g/day)
Normalized protein catabolic rate 1.4 ± 0.5 g/kg/day
(0.6–2.5 g/kg/day)
Higher amino acid intake resulted in less negative nitrogen
balance (-3.5 ± 4.2 g/day ) vs lower amino acid intake
(-8.4 ± 4.9 g/day, p=0.004)
Serum amino acid concentrations normalized only with
amino acid intake at 2.5 g/kg/day
Correlation between amino acid intake and losses (except
tyrosine)
Amino acid losses as percentage of intake at 17%
(range 13–24%)
Nitrogen balance positively related to nitrogen intake
(p=0.0075)
Nitrogen balance more likely achieved with amino acid
intake > 2 g/kg/day (p=0.0001)
Each nitrogen balance increase by 1 g/day increased patient
survival probability by 21%
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study period, effluent volume, and the efficiency
of dialysis.  There was a higher proportion of
amino acid loss as a percentage of amino acid
intake with a dialysate rate of 1.8 L/hour
compared with 0.9 L/hour (6.4 ± 2.5% vs 4.8 ±
1.5%, p<0.0001).  However, amino acid intake
was not predictive of hemodiafilter amino acid
losses.  A study limitation is the choice of a control
group with normal renal function leading to a
baseline mismatch between the control and
treatment groups.
The effect of CAVHD on nitrogen balance was
evaluated in nine critically ill adult patients with
acute kidney injury.58 Patients received amino
acids at 1.25–1.87 g/kg/day with 1850 kcal/day of
nonprotein calories in their parenteral nutrition.
Study results showed a significant average
effluent loss of nitrogen (24.1 g/day) that exceeded
the average nitrogen intake in parenteral nutrition
(20.5 g/day).  This resulted in an average negative
nitrogen balance of -3.6 g/day or -0.045 g/kg/day.
The investigators suggested that increasing amino
acid intake may achieve a positive nitrogen
balance.
A prospective, nonrandomized study evaluated
the variables that may affect nitrogen balance and
protein catabolism in 40 consecutive critically ill
adult patients with acute kidney injury managed
with CVVH.59 Mean amino acid intake in the 34
patients who received parenteral nutrition and/or
enteral nutrition was mean ± SD 1 ± 0.4 g/kg/day
(range 0.3–1.9 g/kg/day) with mean total
nonprotein calories of 28 ± 9 kcal/kg/day (range
13–53 kcal/kg/day).  Study results showed for all
patients a mean PCR of 1.4 ± 0.5 g/kg/day (range
0.6–2.5 g/kg/day).  Patients who received nutrition
support were evaluated based on amino acid
intake of less than 1 g/kg/day (0.7 ± 0.2 g/kg/day)
and greater than or equal to 1 g/kg/day (1.3 ± 0.2
g/kg/day).  A significantly less negative nitrogen
balance was noted in patients who received amino
acids 1 g/kg/day or more compared with those
who received less than 1 g/kg/day (-3.5 ± 4.2 vs
-8.4 ± 4.9 g/day, p=0.004).  Positive nitrogen
balance was achieved in 29.4% of patients who
received amino acids 1 g/kg/day or more, whereas
none of the patients in the less than 1 g/kg/day
group achieved positive nitrogen balance.  The
rate of mortality was not significantly different
between the two groups.  A multivariate regres-
sion analysis of the different caloric and amino
acid intake showed that higher amino acid intake
of 1.5 g/kg/day or more or even more than 2
g/kg/day can achieve positive nitrogen balance
that can be further improved with nonprotein
caloric intake of no more than 30–35 kcal/kg/day.
Of interest, increasing caloric intake in patients
who received amino acids of more than 1.5 g/kg/day
was associated with increased protein catabolism.
At an amino acid intake of more than 2 g/kg/day,
lower caloric intake was associated with improved
nitrogen balance.  To optimize nitrogen retention,
study investigators recommended that critically
ill patients treated with CVVH should receive
amino acids at 1.5–1.8 g/kg/day with caloric
intake of 25–35 kcal/kg/day.
Amino acids at doses of 2 g/kg/day or more
were associated with a greater chance of normalizing
608
Table 1.  Clinical Studies of Amino Acid Requirements in Critically Ill Patients with Acute Kidney Injury Treated with
Continuous Renal Replacement Therapy (continued)
Patient CRRT Modality and
Study Design Population Effluent Rate Amino Acid and Caloric Intake Primary End Points
Prospective, Adults (surgical CVVHD, Parenteral nutrition: Nitrogen balance,
nonrandomized, or medical): CAVHD; Cohort 1: amino acids survival
cohort62 cohort 1 (n=24), 1 or 2 L/hr 1.2 (range 0.41–2.4)
cohort 2 (n=16) g/kg/day
Cohort 2: amino acids
2.5 g/kg/day; nonprotein
calories 30–35 kcal/kg/day
Prospective, Adults with MODS CVVHDF; Parenteral nutrition: amino Amino acid losses
nonrandomized, (n=7) 1 or 2 L/hr acids 2.5 g/kg/day, nonprotein across hemodiafilter,
cohort63 calories 35 kcal/kg/day nitrogen balance
Data are mean, mean ± SD, or range.
CRRT = continuous renal replacement therapy; CVVH = continuous venovenous hemofiltration; CVVHD = continuous venovenous
hemodialysis; CAVHD = continuous arteriovenous hemodialysis; APACHE = Acute Physiology and Chronic Health Evaluation; MODS =
multiorgan dysfunction syndrome; CVVHDF = continuous venovenous hemodiafiltration.
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serum amino acid concentrations and improving
nitrogen balance.  A prospective interventional
study evaluated the effects of different levels of
amino acid intake on serum amino acid concen-
trations, amino acid balance, and amino acid
losses in 11 adult critically ill patients with acute
kidney injury treated with CVVHD.60 All patients
received parenteral nutrition that provided amino
acids initially at 1 g/kg/day then increased at 24-
hour intervals by 0.25 g/kg/day to a maximum of
2.5 g/kg/day.  Mean nonprotein caloric intake was
2585 kcal/day (35 kcal/kg/day).  Study results
showed that, with amino acid dosing at less than
2.5 g/kg/day, 14–57% of serum amino acid
concentrations were below normal range.  Although
keeping caloric intake constant, amino acid
balance became increasingly positive as amino
acid intake increased from 1 to 2.5 g/kg/day
(p=0.0001).  Serum amino acid concentrations
did not normalize until amino acid intake
reached 2.5 g/kg/day.  Overall, amino acid losses
through the hemodiafilter were 17% (13–24%) of
amino acid intake.  Blood urea concentrations
increased with higher amino acid intake but
remained at acceptable average concentrations of
less than 61.6 mg/dl.  The investigators recom-
mended that adult patients treated with CRRT
receive amino acids at 2.5 g/kg/day to correct
amino acid deficiencies and improve nitrogen
retention.  However, combining data from a
diverse patient population with various clinical
conditions may preclude generalization of results.
Of the 11 patients, 3 had multiple trauma and 2
others had extensive burns.  Patients with severe
trauma or burn injuries normally have higher
amino acid requirements to counteract hyper-
catabolism and promote wound healing.  Also,
significant protein losses from draining wounds
and exfoliating burns could not be measured and
could have affected the accuracy of nitrogen
balance studies.  Further, normalization of serum
amino acid concentrations in correlation with
amino acid intake should be interpreted with
caution.  Serum amino acid concentrations depend
not only on amino acid intake, but also on
endogenous breakdown and production as a
function of stress level and degree of injury.
The same investigators further reported in a
prospective interventional study the effects of
high amino acid intake on nitrogen balance and
patient outcomes in 50 sequential adult critically
ill patients with acute kidney injury treated with
CVVHD.61 The treatment group included 40
patients who received amino acids at 1.5 g
/kg/day for 2 days, then 2 g/kg/day for the next 2
days, and then 2.5 g/kg/day for the last 2 days.
Ten patients in the control group received a fixed
amino acid dosage of 2 g/kg/day to eliminate
time-effect on nitrogen balance.  Patients received
enteral nutrition and/or parenteral nutrition
based on tolerance with a caloric intake of mean
± SD 2101 ± 410 kcal/day.  Study results showed
that nitrogen balance was positively related to
amino acid intake (p=0.0075).  Attaining positive
nitrogen balance was more likely with amino acid
intake greater than 2 g/kg/day (p=0.0001).  The
probability of survival increased by 21% for every
1-g/day increase in nitrogen balance.  However,
despite the association of nitrogen balance to
patient morbidity and mortality, the multivariate
analysis, after adjusting for age, sex, diagnosis
category, and Acute Physiology and Chronic
Health Evaluation (APACHE) II score, showed
no significant direct relationship between amino
acid intake and patient outcomes.
A prospective, nonrandomized, cohort study of
40 adult medical and surgical critically ill
patients with acute kidney injury treated with
CAVHD or CVVHD compared the metabolic and
clinical effects of two levels of amino acid
intake.62 One group of 24 patients received par-
enteral amino acids at an average of 1.2 g/kg/day
(range 0.41–2.4 g/kg/day) and a second group of
16 patients received fixed amino acid doses at 2.5
g/kg/day.  Parenteral nutrition provided patients
in both groups with nonprotein calories at 30–35
kcal/kg/day. In contrast to previous results, study
results showed that nitrogen loss was greater in
patients who received higher amino acid intake,
but effluent amino acid losses were similar in
both groups.  Patients in the high amino acid
intake group had a less negative mean nitrogen
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Table 1.  (continued)
Results
High amino acid intake resulted in less negative nitrogen
balance (-1.92 g/day) vs low amino acid intake (-5.5 g/day,
p=0.176)
Effluent daily amino acid losses similar between groups
Survival similar between groups
High amino acid intake caused higher plasma urea
concentrations, requiring more aggressive dialysis
Median amino acid losses of 12 g/day (5–21% of daily
amino acid intake)
Median nitrogen balance -1.8 g/day (range -21 to +17.9
g/day)
Positive nitrogen balance 35% of time
No effect on improvement in patient outcome
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balance compared with the lower intake group,
although the difference did not achieve statistical
significance (-1.92 vs -5.5 g/day, p=0.176).  Also,
despite greater nitrogen loss, the high amino acid
intake group had a higher percentage of treat-
ment days in positive nitrogen balance compared
with the lower amino acid intake group (53.6%
vs 36.7%, p<0.05).  However, high amino acid
intake was associated with a higher mean plasma
urea concentration compared with lower amino
acid intake (26.6 vs 18 mmol/L, p<0.0001) and
thus required more aggressive dialysis to control
azotemia.  No significant difference in survival
rates was shown between the two groups.
Although the investigators speculated that amino
acid intake of greater than 3 g/kg/day may be
needed to reach close-to-neutral nitrogen
balance, they proposed an amino acid intake at
1.8–2 g/kg/day as an optimal compromise to
improve nitrogen balance and avoid worsening of
azotemia.
The same investigators later evaluated the
effects of high parenteral amino acid doses at 2.5
g/kg/day on nitrogen balance in seven adult
critically ill patients with acute kidney injury
who had multiorgan dysfunction syndrome
treated with CVVHDF.63 All patients received
parenteral nutrition that provided nonprotein
calories at 35 kcal/kg/day.  Study results showed
median amino acid losses of 12 g/day (5–21% of
daily amino acid intake).  Median nitrogen
balance was slightly negative at -1.8 g/day (range
-21 to +17.9 g/day) with a positive nitrogen
balance achieved in 7 of the 20 study days.
Plasma urea concentrations were maintained at a
median 75.4 mg/dl.  The investigators concluded
that amino acid intake at 2.5 g/kg/day in adult
critically ill patients with acute kidney injury
treated with CRRT can provide near-neutral to
positive amino acid balance while maintaining
azotemic control.
Impact of Nutritional Status and Amino Acid
Intake on Patient Outcomes
Severe malnutrition occurs in up to 42% of
patients with acute kidney injury.  Severely mal-
nourished patients have a significantly increased
in-hospital length of stay, increased risk for
comorbidities (sepsis, septic shock, hemorrhage,
intestinal occlusion, cardiac dysrhythmia, cardio-
genic shock, acute respiratory failure), and
increased in-hospital mortality.64 Therefore,
optimizing nutritional status in these patients is
important to improve patient outcome.
Protein catabolism results in malnutrition and
predisposes patients to increased morbidity and
mortality.65, 66 Although attaining a positive
nitrogen balance may not always be possible in
critically ill patients, optimizing protein and
caloric intake in patients managed with CRRT
will improve nitrogen balance.  In clinical studies,
there was no improvement in patient survival
and clinical outcomes despite increasing amino
acid intake and improving nitrogen balance.59, 62, 63
One of the limitations addressed by the investi-
gators was that studies were too small to detect a
difference.63 Also, there was no association
between positive nitrogen balance and patient
number of days receiving ventilation, or hospital
or ICU length of stay.61 Results of nitrogen
balance studies in critically ill patients should be
interpreted with caution due to the heterogeneity
of the critically ill population; the variability in
nitrogen intake, metabolism, and losses; and the
limitations of traditional nitrogen balance equa-
tions.  Although nitrogen balance studies provide
an idea about nitrogen retention, they do not
provide information about amino acid pharmaco-
kinetics or whole-body protein turnover including
protein synthesis and breakdown.67
Amino acid intake during dialysis increases net
muscle protein synthesis but does not decrease
protein breakdown.68 In patients receiving
maintenance intermittent hemodialysis, amino
acid losses in the dialysate lower serum amino
acid concentrations, but intracellular amino acid
concentrations remain unchanged probably due
to enhanced intracellular amino acid transport.69
Increasing amino acid intake increases serum
amino acid concentrations, and a linear correlation
exists between plasma amino acid concentrations
and stimulation of muscle protein synthesis.
However, the maximal capacity for stimulation of
muscle protein synthesis is reached with only
little increases in protein synthesis at serum
amino acid concentrations greater than 2.5 times
the normal postabsorptive serum amino acid
concentrations.  Therefore, amino acid intake in
amounts that exceed muscle protein synthetic
capacity may alternatively be oxidized or used for
ureagenesis and gluconeogenesis.70, 71
Little is known about the safety and physiologic
effects of increasing individual amino acid intake
in patients with acute kidney injury.  In experi-
mental models of acute kidney injury, amino
acids such as glycine, alanine, and taurine showed
potential renal protective effects by limiting renal
tubular injury, whereas methionine, serine, and
lysine may be nephrotoxic.26, 72–75 The role of
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arginine in critical illness and in immunocompro-
mised patients is widely debated.  Arginine may
have immunomodulatory effects, is essential for
lymphocyte function, and is a precursor of nitric
oxide.  Although nitric oxide may have positive
antiinflammatory effects and improve micro-
vascular and renal blood flow, it may mediate
tissue damage in patients with sepsis.76–80 It is
debatable whether nitric oxide is nephrotoxic or
has renal protective effects.  In animal studies of
rats with induced ischemic acute kidney injury,
increased L-arginine transport and nitric oxide
production worsened renal tubular injury during
the reperfusion period through the formation of
peroxynitrite.80 In contrast, nitric oxide release
by L-arginine was shown to improve renal
hemodynamics in ischemic acute kidney injury
in rats and partially reduce kidney dysfunction
induced by cyclosporine.81, 82
Conclusion
Protein catabolism is unavoidable in critically
ill patients and results in negative nitrogen
balance.  Caloric and protein intake both affect
nitrogen retention.  In clinical studies of critically
ill patients with acute kidney injury treated with
CRRT, amino acid losses ranged widely from
5–21% of amino acid intake.  Differences in
patient populations, sample sizes, study
outcomes, dialytic modalities, effluent rates, and
hemodiafilter properties may have caused this
wide variation.  At the clinically common effluent
rate of 2 L/hour, it is reasonable to estimate
amino acid losses at about 10–15% of amino acid
intake.  However, because amino acid clearance
through CRRT correlates with serum amino acid
concentrations rather than amino acid intake, it
may be more appropriate to quantify amino acid
losses in gram amounts rather than in percentage
of amino acid intake.  For an effluent rate of 2
L/hour, amino acid losses ranged from 5–15
g/day with the higher losses corresponding with
the high amino acid intake.  Amino acid losses of
15 g/day translate to an equivalent amino acid
loss of 0.2 g/kg/day for an adult weighing 75 kg.
Normally, critically ill adult patients receive
amino acids at 1.5–2 g/kg/day.  Practically, adding
amino acids at 0.2 g/kg/day to compensate for
effluent losses would amount to amino acid doses
of 1.7–2.2 g/kg/day for critically ill adult patients
treated with CRRT.
In comparison, clinical studies reported
improved nitrogen balance with high amino acid
intake at 2.5 g/kg/day.  However, the correlation
between improved nitrogen balance and patient
outcome remains unknown.  Amino acid intake
should be tailored to the specific patient needs.
Patients with hepatic encephalopathy are
intolerant to high protein intake and require
lower amino acid dosing.  Patients with trauma,
burns, and sepsis are hypercatabolic and benefit
from higher amino acid intake.  Data from large,
randomized, controlled studies are needed to
define the optimal amino acid dosing regimen in
patients managed with CRRT, as well as the safety
of high amino acid intake and its effects on
patient morbidity and survival.
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